EuroGeneTest
EuroGeneTest is a 5-year, €10 million ($13.1 million) project involving 100 accredited labs that aims to help European labs and manufacturers evaluate new technologies.
Fetal and NeoNatal Evaluation Network (SAFE)
The SAFE program is being conducted with Network of Excellence partner the London Institute of Child Health, and with researchers from Bristol University.
Milestones
Ferbruary 2007: EuroGentest announced that it is evaluating a pyrophosphorolysis activated polymerization assay (PAP assay) for prenatal screening through Europe’s Special Non-invasive Advances in Fetal and NeoNatal Evaluation Network (SAFE) and another of its Excellence programs.
The PAP assay is a non-invasive prenatal screening test. It uses maternal plasma to detect rare mutations and to determine fetal sex.